<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01825941</url>
  </required_header>
  <id_info>
    <org_study_id>HEDNET3</org_study_id>
    <nct_id>NCT01825941</nct_id>
  </id_info>
  <brief_title>Diphenhydramine for Acute Migraine</brief_title>
  <official_title>Diphenhydramine as Adjuvant Therapy for Acute Migraine. A Randomized Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Parenteral diphenhydramine is commonly used as adjuvant therapy for acute migraine despite
      the fact that data supporting this practice do not exist. The investigators propose a
      randomized double blind study to test the hypothesis that 50mg of intravenous
      diphenhydramine, when added to standard migraine therapy, will result in a greater rate of
      sustained headache relief than standard migraine therapy alone. For this study, standard
      migraine therapy will be 10mg of intravenous metoclopramide. Sustained headache relief is
      defined as achieving a headache level of &quot;mild&quot; or &quot;none&quot; within two hours and maintaining a
      level of &quot;mild&quot; or &quot;none&quot; for 48 hours. Patients who present to the Montefiore emergency room
      (Bronx, NY) with an acute migraine will be approached for participation. They will be
      screened for medication contra-indications and non-migraine etiologies of headache. The study
      will be randomized. Assignment will be concealed. Participants and researchers will be
      blinded. Efficacy outcomes and adverse events will be assessed every half hour for two hours
      in the ED and by telephone 48 hours after medication administration. A sample size
      calculation, based on pilot data, revealed the need for 374 participants. An interim analysis
      will be performed after 200 participants have been enrolled with the goal of assessing for
      lack of conditional power.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained headache relief</measure>
    <time_frame>48 hours</time_frame>
    <description>Obtaining a headache level = &quot;mild&quot; or &quot;none&quot; and maintaining a headache level = &quot;mild&quot; or &quot;none&quot; for 48 hours</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">374</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Metoclopramide + Diphenhydramine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metoclopramide 10 milligrams + Diphenhydramine 50 milligrams, administered as an intravenous drip over 15 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metoclopramide + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Metoclopramide 10mg + placebo, administered intravenously over 15 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metoclopramide</intervention_name>
    <description>10 milligrams, administered intravenously over 15 minutes</description>
    <arm_group_label>Metoclopramide + Diphenhydramine</arm_group_label>
    <arm_group_label>Metoclopramide + placebo</arm_group_label>
    <other_name>Reglan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>diphenhydramine</intervention_name>
    <description>50 milligrams, administered intravenously over 15 minutes</description>
    <arm_group_label>Metoclopramide + Diphenhydramine</arm_group_label>
    <other_name>Benadryl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Metoclopramide + placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute migraine headache

          -  Present to our emergency room in the Bronx, NY for treatment of migraine headache

        Exclusion Criteria:

          -  Temperature &gt; 100.3 F

          -  Pheochromocytoma

          -  Seizure disorder

          -  Parkinson's disease

          -  Use of MAO inhibitors

          -  Use of anti-rejection transplant medications

          -  Use of potassium supplements

          -  Use of pramlintide
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2013</study_first_submitted>
  <study_first_submitted_qc>April 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2013</study_first_posted>
  <last_update_submitted>March 19, 2015</last_update_submitted>
  <last_update_submitted_qc>March 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montefiore Medical Center</investigator_affiliation>
    <investigator_full_name>Benjamin Friedman</investigator_full_name>
    <investigator_title>Associate professor of Emergency Medicine</investigator_title>
  </responsible_party>
  <keyword>migraine</keyword>
  <keyword>headache</keyword>
  <keyword>metoclopramide</keyword>
  <keyword>diphenhydramine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Metoclopramide</mesh_term>
    <mesh_term>Promethazine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>May 7, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

